Evidence map›Paper›PMID 39989343›Full record

ArticleJournal of comparative effectiveness research2025

Matching-adjusted indirect comparisons of efficacy outcomes between etrasimod and ozanimod for moderately to severely active ulcerative colitis.

Vipul Jairath, Tim Raine, Thomas P Leahy, Ravi Potluri, Karolina Wosik, David Gruben, Joseph C Cappelleri, Peter Hur, Lauren Bartolome

Abstract readComparative Study
In one paragraph

Article in Journal of comparative effectiveness research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Vipul JairathDepartment of Medicine & Department of Epidemiology & Biostatistics, Western University, London, ON, N6G 2M1, Canada.ORCID 0000-0002-1092-0033
Tim RaineDepartment of Gastroenterology, Addenbrooke's Hospital, Cambridge University Teaching Hospitals NHS Foundation Trust, Cambridge, UK.ORCID 0000-0002-5855-9873
Thomas P LeahyPutnam Associates LLC, Toronto, ON, M5V 3T5, Canada.ORCID 0000-0003-3958-6224
Ravi PotluriPutnam Associates LLC, New York, NY 10282, USA.ORCID 0000-0002-0509-2659
Karolina WosikPfizer Canada, Kirkland, QC, H9J 2M5, Canada.ORCID 0009-0002-7233-0933
David GrubenPfizer Inc, Groton, CT 06340, USA.
Joseph C CappelleriPfizer Inc, Groton, CT 06340, USA.ORCID 0000-0001-9586-0748
Peter HurPfizer Inc, New York, NY 10017, USA.
Lauren BartolomePfizer Inc, New York, NY 10017, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Colitis, UlcerativeIndansOxadiazolesSphingosine 1 Phosphate Receptor ModulatorsAdultFemaleHumansMaleMiddle AgedSeverity of Illness IndexTreatment OutcomeIndansOxadiazolesozanimodSphingosine 1 Phosphate Receptor Modulatorsetrasimodmatching-adjusted indirect comparisonozanimodulcerative colitis

Identifiers

PMID39989343
PMCPMC11963346

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.